Novo Nordisk
NVO
£40.39
Share price
-21.83%
Change (1 day)
-59.51%
Change (1 year)
Categories
Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
Novo Nordisk (NVO) - Total debt
Total debt on the balance sheet as of March 2025 : £12.89 Billion
According to Novo Nordisk's latest financial reports the company's total debt is £12.89 Billion. A company’s total debt is the sum of all current and non-current debts.
Novo Nordisk - Total debt on balance sheet (from 1996 to 2025)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2024-12-31 | £11.42 B | 264.04% |
| 2023-12-31 | £3.13 B | 2.29% |
| 2022-12-31 | £3.06 B | 2.13% |
| 2021-12-31 | £3.00 B | 139.3% |
| 2020-12-31 | £1.25 B | 145.01% |
| 2019-12-31 | £0.51 B | 724.61% |
| 2018-12-31 | £62.16 M | -69.24% |
| 2017-12-31 | £0.20 B | 668.97% |
| 2016-12-31 | £26.27 M | -75.24% |
| 2015-12-31 | £0.10 B | 40.48% |
| 2014-12-31 | £75.53 M | 213% |
| 2013-12-31 | £24.13 M | -56.01% |
| 2012-12-31 | £54.85 M | -42.63% |
| 2011-12-31 | £95.6 M | -62.82% |
| 2010-12-31 | £0.25 B | 55.61% |
| 2009-12-31 | £0.16 B | -44.45% |
| 2008-12-31 | £0.29 B | 121.14% |
| 2007-12-31 | £0.13 B | -1.88% |
| 2006-12-31 | £0.13 B | -44.53% |
| 2005-12-31 | £0.24 B | 52.72% |
| 2004-12-31 | £0.16 B | -1.2% |
| 2003-12-31 | £0.16 B | 20.89% |
| 2002-12-31 | £0.13 B | -25.66% |
| 2001-12-31 | £0.18 B | -1.56% |
| 2000-12-31 | £0.18 B | -4.64% |
| 1999-12-31 | £0.19 B | -25.24% |
| 1998-12-31 | £0.25 B | -12.2% |
| 1997-12-31 | £0.29 B | 40.78% |
| 1996-12-31 | £0.21 B |
Total debt for similar companies or competitors
| Company | Total debt/th> | differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | £45.89 B | 256.00% | 🇺🇸 USA |
 Eli Lilly LLY | £28.84 B | 123.72% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | £38.36 B | 197.62% | 🇺🇸 USA |
 Sanofi SNY | £17.05 B | 32.26% | 🇫🇷 France |